Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis

ABSTRACT: Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis

PROVIDER: PRJNA937236 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23573600_1.fastq.gz	Fastqsanger.gz
	SRR23573600_2.fastq.gz	Fastqsanger.gz
	SRR23573601_1.fastq.gz	Fastqsanger.gz
	SRR23573601_2.fastq.gz	Fastqsanger.gz
	SRR23573602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 148

Similar Datasets

Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis

Project description:The purpose of this study was to investigate the transcriptomic heterogeneity in synovial tissue of early untreated rheumatoid arthritis patients in association with clinical data

2023-05-31 | GSE225731 | GEO

CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis

Project description:Macrophage polarization and synovitis play significant roles in rheumatoid arthritis (RA). Chemokines are involved almost throughout the entire pathology of synovitis. However, the interaction between chemokines and macrophage polarization in RA has been seldom reported. This study found that chemokine C-C motif ligand 7 (CCL7) secreted by polarized M1 macrophages enhances M1 polarization, creating a positive feedback loop and revealing the role of CCL7 in the progression of rheumatoid arthritis. In this research, RNA sequencing indicated that M1 polarized macrophages secrete a large amount of CCL7, which further enhances M1 polarization. Through immunohistochemistry and enzyme-linked immunosorbent assay, it was found that the expression of CCL7 in the synovial tissue and serum of RA patients and mice was upregulated. Intra-articular injection of CCL7 recombinant protein exacerbated M1 polarization of macrophages, inflammation, fibrosis in the synovial tissue, and worsened arthritis pain in mice, which was improved after the injection of CCL7 neutralizing antibody. In addition, CCL7 promoted M1 polarization of macrophages and reversed the M2 polarization induced by IL-4, and it also promoted macrophage proliferation and migration. Although it had an inhibitory effect on chondrocyte activity, it did not show a significant impact on chondrocyte metabolism. Mechanistically, CCL7 targets CCR1 to promote M1 polarization of macrophages, a process partly mediated through the activation of the JAK2/STAT1 pathway. When stimulated by CCL7, macrophages secreted a vast amount of pro-inflammatory factors, exacerbating synovitis and cartilage damage, leading to the aggravation of RA disease. Our research established a positive feedback loop between M1 polarization of macrophages and CCL7, indicating that blocking CCL7 could improve the progression of RA, suggesting CCL7 as a potential target for RA treatment.

2025-01-08 | GSE267151 | GEO

CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis II

2025-01-08 | GSE285977 | GEO

CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis

Project description:CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis

| PRJNA1109863 | ENA

CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis II

Project description:CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis II

| PRJNA1207088 | ENA

Cell cycle positioning drives heterogeneity within the pluripotent stem cell compartment

Project description:Heterogeneity in pluripotent cells marks a metastable state where cells may drift between native and lineage-primed populations. While the role for these heterogeneities are unclear, they may reflect the dynamic equilibriums of signaling networks and have a direct effect on differentiation potentialities. Here, we report the role of the cell cycle in establishing heterogeneity of human pluripotent stem cells. By utilizing the FUCCI cell cycle indicator system coupled to fluorescent activated cell sorting (FACS), we have uncovered that the cell cycle drives heterogeneity at the epigenetic, transcriptional and post-transcriptional levels. Our data show widespread dynamics in 5-hydroxymethylcytosine (5hmC) during the cell cycle. Furthermore, transcript profiling by RNA-sequencing identified >500 genes that were cell cycle-regulated, of which the largest cohort of genes were transcriptional regulators. In sum, we demonstrate the role of the cell cycle in coordinating cellular transitions between metastable states in pluripotent stem cells. mRNA sequencing of the cell cycle phases; early & late G1, S and G2/S from human ES cells in triplicate.

2013-12-19 | E-GEOD-53481 | biostudies-arrayexpress

PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma

Project description:PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma

| PRJNA848783 | ENA

Rheumatoid arthritis

Project description:Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease of unknown etiology and pronounced inter-patient heterogeneity. To characterize RA at the molecular level and to uncover key pathomechanisms, we performed whole-genome gene expression analyses. Synovial tissues from rheumatoid arthritis patients were compared to those from osteoarthritis patients and to normal donors. Keywords: disease state analysis

2004-11-04 | GSE1919 | GEO

Effects of methotrexate and tofacitinib on gene expression of activated rheumatoid arthritis fibroblast-like synoviocytes

Project description:Activated fibroblast-like synoviocytes (FLS) are drivers of synovitis and structural joint damage in rheumatoid arthritis (RA). Despite the use of disease-modifying drugs, only about 50% of RA patients reach remission in real-world settings. We used an unbiased approach to investigate the effects of standard-of-care methotrexate (MTX) and a Janus kinase inhibitor, tofacitinib (TOFA), on gene expression in RA-FLS, in order to identify untargeted disease mediators.

2024-10-04 | GSE266310 | GEO

PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma [Human]

Project description:PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma [Human]

| PRJNA848779 | ENA